Neurocrine Biosciences Inc (NBIX) Financials
Key financial figures for Neurocrine Biosciences Inc (Q2 2026).
Neurocrine Biosciences, Inc. reported revenue of $959.0 million for Q2 FY2026, up 39.5% from the same period a year earlier. Net income was $144.4 million, or $1.39 per share. Operating margin came to 15.95%, against 21.18% a year earlier. Free cash flow for the period was $128.6 million. Across the last 5 reported quarters, quarterly revenue has risen from $687.5 million in Q2 FY2025 to $959.0 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Neurocrine Biosciences, Inc. are on the SentiSense financials page.
- Revenue
- $959M
- Net Income
- $144M
- EPS
- $1.43
- Total Assets
- $5.4B
- Operating Cash Flow
- $136M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $959M | $144M | $1.39 | 15.95% | $129M |
| Q1 FY2026 | $815M | $198M | $1.91 | 22.84% | $137M |
| Q4 FY2025 | $806M | $154M | $1.48 | 26.18% | |
| Q3 FY2025 | $795M | $210M | $2.04 | 30.07% | $214M |
| Q2 FY2025 | $688M | $108M | $1.06 | 21.18% | $90M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $2.9B | $479M | $4.67 | 21.64% | $749M |
| FY2024 | $2.4B | $341M | $3.29 | 24.22% | $557M |
| FY2023 | $1.9B | $250M | $2.47 | 13.3% | $362M |
Frequently asked questions
What was Neurocrine Biosciences, Inc.'s revenue last quarter?
Neurocrine Biosciences, Inc. reported revenue of $959.0 million for Q2 FY2026, up 39.5% from the same period a year earlier.
Is Neurocrine Biosciences, Inc. profitable?
Yes. Neurocrine Biosciences, Inc. reported net income of $144.4 million for Q2 FY2026, a net margin of 15.06% on revenue.
How has Neurocrine Biosciences, Inc.'s margin trended?
Operating margin was 15.95% in Q2 FY2026, compared with 21.18% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Neurocrine Biosciences, Inc. generate?
Neurocrine Biosciences, Inc. generated free cash flow of $128.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Neurocrine Biosciences Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.